Login to Your Account

Lpath comes up short in renal cell carcinoma study; shares fall

By Peter Winter
BioWorld Insight Editor

Wednesday, March 25, 2015
Lpath Inc. saw its shares tumble in heavy trading following the release of news that its phase IIa single-agent, open-label study of Asonep did not meet the primary endpoint of statistically significant PFS in patients with advanced RCC.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription